AMRX Amneal Pharmaceuticals, Inc.
Healthcare$12.79+2.98%ClosedMarket Cap: $4.08B
As of 2026-05-26
Valuation
P/E (TTM)
54.75
PEG
0.34
P/B
-89.96
P/S
1.30
EV/EBITDA
10.32
DCF Value
$16.41
FCF Yield
5.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
38.7%
Operating Margin
11.8%
Net Margin
4.0%
ROE
-144.7%
ROA
3.5%
ROIC
12.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $722.5M | 44.3% | $133.5M | $62.5M | $— | — |
| Q4 null | $814.3M | 36.5% | $114.5M | $35.1M | $— | — |
| FY null | $3.02B | 37.6% | $423.1M | $72.1M | $— | — |
| Q3 null | $784.5M | 34.9% | $-117.0K | $2.4M | $— | — |
| Q2 null | $724.5M | 39.5% | $111.4M | $22.4M | $— | — |
| Q1 null | $695.4M | 36.8% | $100.3M | $12.2M | $— | — |
| Q4 null | $730.5M | 36.0% | $75.8M | $-31.1M | $— | — |
| FY null | $2.79B | 36.5% | $249.3M | $-116.9M | $— | — |
| Q3 null | $702.5M | 38.4% | $88.8M | $-156.0K | $— | — |
| Q2 null | $701.8M | 35.6% | $95.5M | $6.0M | $— | — |
| Q1 null | $659.2M | 36.1% | $-10.7M | $-91.6M | $— | — |
| Q4 2023 | $617.0M | 36.5% | $14.2M | $-98.6M | $-0.40 | — |